scispace - formally typeset
M

Mariam Jafri

Publications -  3
Citations -  231

Mariam Jafri is an academic researcher. The author has contributed to research in topics: Trastuzumab & Taxane. The author has an hindex of 2, co-authored 3 publications receiving 154 citations.

Papers
More filters
Journal ArticleDOI

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena M. Earl, +117 more
- 29 Jun 2019 - 
TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.
Journal ArticleDOI

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

Thomas Bachelot, +291 more
- 01 May 2019 - 
TL;DR: Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile and preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumAB and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA.
Journal ArticleDOI

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, +370 more
- 01 Oct 2021 - 
TL;DR: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumabs (CLEOPATRA) trial established the combination of pertuzumaab, trastuzumaba and docetaxel as standard first-line therapy for locally recurrent/metastatic breast cancer (LR/mBC).